Efficacy and treatment satisfaction of once-daily insulin glargine plus one or two oral antidiabetic agents versus continuing premixed human insulin in patients with type 2 diabetes previously on long-term conventional insulin therapy: The switch pilot study

Experimental and Clinical Endocrinology and Diabetes

Volumn 115, Issue 10, 2007, Pages 627-633

  Schiel, R ^a,b   Müller, Ulrich A ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b Inselklinik Heringsdorf GmbH   (Germany)

Author keywords

Glimepiride; Hypoglycemia; Insulin glargine; Metformin; Treatment satisfaction

Indexed keywords

GLIMEPIRIDE; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN GLARGINE; METFORMIN; ORAL ANTIDIABETIC AGENT;

ADULT; AGE DISTRIBUTION; AGED; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SATISFACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; BLOOD GLUCOSE; BODY MASS INDEX; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; METFORMIN; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; SULFONYLUREA COMPOUNDS; TIME FACTORS;

EID: 36849060330     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-984445     Document Type: Review

References (42)

1. Berger M, Grüßer M, Jürgens V et al Behandlungs- und Schulungsprogramm für Typ-II-Diabetiker, die Insulin spritzen. Deutscher Ärzte-Verlag, Cologne, Germany, 1994
2. Berger M, Heinemann L. Are presently available insulin analogues clinically beneficial? Diabetologia 1997; 40: S91-S96
3. Berger M, Jorgens V, Flatten G. Health care for persons with non-insulin-dependent diabetes mellitus. The German experience. Ann Intern Med 1996; 124: 153-155
4. Berger M, Jorgens V, Muhlhauser I. Rationale for the use of insulin therapy alone as the pharmacological treatment of type 2 diabetes. Diabetes Care 1999; 22 (Suppl 3):C71-C75
5. Bolli GB, Marchi RD Di, Park GD, Pramming S, Koivisto VA. Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia 1999; 42: 1151-1167
6. Bradley C. The Diabetes Treatment Satisfaction Questionnaire: DTSQ. In: Bradley C, editor. Handbook of Psychology and Diabetes: a guide to psychological measurement in diabetes research and practice. Chur, Switzerland: Harwood Academic Publishers, 1994
7. Davies M, Storms F, Gomis R, AT.LANTUS study group. Insulin glargine-based therapy improves glycemic control in patients with Type 2 diabetes sub-optimally controlled on premixed insulin therapies. Diabetes 2006; 55: A108 (Abstract 455-P).
8. Davies M, Storms F, Shutter S, Bianchi-Biscay M, Gomis R. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care 2005; 28: 1282-1288
9. DCCT. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329: 977-986
10. Eliaschewitz FG, Calvo C, Valbuena H et al. Therapy in type 2 diabetes: insulin glargine vs NPH insulin both in combination with glimepiride. Arch Med Res 2006; 37: 495-501
11. European Diabetes Policy Group. A desktop guide to Type 2 diabetes mellitus. European Diabetes Policy Group 1999. Diabetic Med 1999; 16: 716-730
12. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997; 20: 1183-1197
13. Fritsche A, Schweitzer MA, Haring HU. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med 2003; 138: 952-959
14. Grüßer M, Hartmann P, Schlottmann N, Jörgens V. Structured treatment and teaching programme for type 2 diabetic patients on conventional insulin treatment: evaluation of reimbursement policy. Pat Educ Couns 1996; 29: 123-130
15. Grüßer M, Jörgens V, Berger M. Vor dem Essen Insulin Für die flexible Behandlung des Typ-2-Diabetes mit Normalinsulin. Kirchheim-Verlag Mainz, Germany, 1999
16. Harris M. Medical care for patients with diabetes. Epidemiologic aspects. Ann Intern Med 1996; 124: 117-122
17. Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000; 23: 644-649
18. Hermann LS. Optimising therapy for insulin-treated type 2 diabetes mellitus. Drugs Aging 2000; 17: 283-294
19. Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Jarvinen H. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005; 28: 254-259
20. Joergens V, Gruesser M. Three years' experience after national introduction of teaching programs for type II diabetic patients in Germany: how to train general practitioners. Patient Educ Couns 1995; 26: 195-202
21. Jonsson B. Revealing the cost of type II diabetes in Europe. Diabetologia 2002; 45: S5-S12
22. Kalfhaus J, Berger M. Insulin treatment with preprandial injections of regular insulin in middle-aged type 2 diabetic patients. A two years observational study. Diabetes Metab 2000; 26: 197-201
23. Massi Benedetti M. The cost of diabetes type II in Europe. Diabetologia 2002; 45: S1-S4
24. Müller UA, Muller R, Starrach A et al. Should insulin therapy in type 2 diabetic patients be started on an out- or inpatient basis? Results of a prospective controlled trial using the same treatment and teaching programme in ambulatory care and a university hospital. Diabetes Metab 1998; 24: 251-255
25. Ohkubo Y, Kishikawa H, Araki E et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-117
26. Pimenta W, Korytkowski M, Mitrakou A et al. Pancreatic beta-cell dysfunction as the primary genetic lesion in NIDDM. Evidence from studies in normal glucose-tolerant individuals with a first-degree NIDDM relative. JAMA 1995; 273: 1855-1861
27. Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA. Less hypoglycemia with insulin glargine in intensive insulin therapy for Type 1 diabetes. Diabetes Care 2000; 23: 639-643
28. Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 1993; 329: 304-309
29. Riddle M, Rosenstock J, Gerich J, Insulin Glargine 4002 Study Investigators. The Treat-to-Target Trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080-3086
30. Riddle M, Rosenstock J, Gerich J, Investigators IGS. The Treat-to-Target Trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080-3086
31. Rosenstock J. Insulin therapy: optimizing control in type 1 and type 2 diabetes. Clin Cornerstone 2001; 4: 50-64
32. Schiel R, Braun A, Rillig A, Ross I, Müller U. Patient education and better general health care improve the outcome of insulin therapy - A prospective, population-based survey (JEVIN). Diabetologia 2002; 45: A314
33. Schiel R, Drewelow S, Martin C et al. Präzision und Richtigkeit häufig benutzter Taschenreflektometer zur Blutzuckerschnellbestimmung: One Touch Basic, One Touch II, One Touch Profile und Gluco Touch. Diab Stoffw 1998; 7: 86-90
34. Schiel R, Muller U, Sprott H et al. The JEVIN-trial: A population-based survey on the quality of diabetes care in Germany - 1994/95 compared to 1989/90. Diabetologia 1997; 40: 1350-1357
35. Schreiber SA, Russmann A. Insulin glargine and educational intervention in patients with type 2 diabetes in clinical practice: long-term improvement in glycaemic control without weight gain. Exp Clin Endocrinol Diabetes 2006; 114: 41-42
36. Standl E, Maxeiner S, Raptis S. Once-daily insulin glargine administration in the morning compared to bedtime in combination with morning glimepiride in patients with type 2 diabetes: an assessment of treatment flexibility. Horm Metab Res 2006; 38: 172-177
37. Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Bmj 2000; 321: 405-412
38. UKPDS. Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years (UKPDS 13). BMJ 1995; 310: 83-88
39. UKPDS. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). (UK Prospective Diabetes Study Group). Lancet 1998; 352: 837-853
40. Yki-Järvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care 2000; 23: 1130-1136
41. Yki-Järvinen H, Kauppila M, Kujansuu E et al. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1992; 327: 1426-1433
42. Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 2006; 49: 442-451